TW202207907A - 細胞素釋放及細胞素風暴之抑制 - Google Patents

細胞素釋放及細胞素風暴之抑制 Download PDF

Info

Publication number
TW202207907A
TW202207907A TW110125635A TW110125635A TW202207907A TW 202207907 A TW202207907 A TW 202207907A TW 110125635 A TW110125635 A TW 110125635A TW 110125635 A TW110125635 A TW 110125635A TW 202207907 A TW202207907 A TW 202207907A
Authority
TW
Taiwan
Prior art keywords
curcumin
virus
cytokines
disease
cytokine
Prior art date
Application number
TW110125635A
Other languages
English (en)
Chinese (zh)
Inventor
彼德 Ｐ 索迪羅
羅倫斯 海爾森
Original Assignee
美商標徑製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/945,195 external-priority patent/US20200360300A1/en
Application filed by 美商標徑製藥公司 filed Critical 美商標徑製藥公司
Publication of TW202207907A publication Critical patent/TW202207907A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
TW110125635A 2020-07-31 2021-07-13 細胞素釋放及細胞素風暴之抑制 TW202207907A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/945,195 US20200360300A1 (en) 2014-12-31 2020-07-31 Suppression of Cytokine Release and Cytokine Storm
US16/945,195 2020-07-31

Publications (1)

Publication Number Publication Date
TW202207907A true TW202207907A (zh) 2022-03-01

Family

ID=80036956

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110125635A TW202207907A (zh) 2020-07-31 2021-07-13 細胞素釋放及細胞素風暴之抑制

Country Status (9)

Country Link
EP (1) EP4188398A1 (ja)
JP (1) JP2023536833A (ja)
KR (1) KR20230026468A (ja)
CN (1) CN116710123A (ja)
AU (1) AU2021315452A1 (ja)
CA (1) CA3189374A1 (ja)
MX (1) MX2023001145A (ja)
TW (1) TW202207907A (ja)
WO (1) WO2022026170A1 (ja)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2875470C (en) * 2012-06-14 2021-01-12 Universitaet Bern Tailored liposomes for the treatment of bacterial infections
US10286065B2 (en) * 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
US20200360300A1 (en) * 2014-12-31 2020-11-19 Signpath Pharma, Inc. Suppression of Cytokine Release and Cytokine Storm
US10898483B2 (en) * 2015-12-23 2021-01-26 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through

Also Published As

Publication number Publication date
KR20230026468A (ko) 2023-02-24
CA3189374A1 (en) 2022-02-03
JP2023536833A (ja) 2023-08-30
AU2021315452A1 (en) 2023-02-02
CN116710123A (zh) 2023-09-05
MX2023001145A (es) 2023-03-06
EP4188398A1 (en) 2023-06-07
WO2022026170A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
US10739353B2 (en) Suppression of cytokine release and cytokine storm
US20200360300A1 (en) Suppression of Cytokine Release and Cytokine Storm
Liu et al. Microglia and CNS interleukin-1: beyond immunological concepts
Martinez et al. The role of chloroquine and hydroxychloroquine in immune regulation and diseases
Sanders Sildenafil for the treatment of Alzheimer’s disease: A systematic review
US11179412B2 (en) Methods of treating conditions involving elevated inflammatory response
Hemdan et al. Modulating sphingosine 1‐phosphate signaling with DOP or FTY720 alleviates vascular and immune defects in mouse sepsis
Guan et al. Dysregulated chemokine signaling in cystic fibrosis lung disease: a potential therapeutic target
CN111655267A (zh) 预防或治疗鼻病毒感染的药物
EP3823658A2 (en) Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders
Zhang et al. Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells
Wang et al. The potential therapeutic role of the HMGB1-TLR pathway in epilepsy
JP2024528731A (ja) 眼癌転移を予防するためのイブジラスト
HRP960070A2 (en) Use of quinoxaline and protease inhibitors in a composition for the treatment of aids and/or hiv infections
Wang et al. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases
Fritsch et al. The role of STING signaling in central nervous system infection and neuroinflammatory disease
Yang et al. Discovery of novel aporphine alkaloid derivative as potent TLR2 antagonist reversing macrophage polarization and neutrophil infiltration against acute inflammation
TW202207907A (zh) 細胞素釋放及細胞素風暴之抑制
Xie et al. Cytosolic DNA sensors in neurodegenerative diseases: from physiological defenders to pathological culprits
WO2022020514A1 (en) Compositions and methods of treating age-related retinal dysfunction
WO2021258206A1 (en) Water-soluble artesunate-based therapy for coronavirus infection
US20210205325A1 (en) Methods of treating a subject having an infectious disease
WO2019246520A1 (en) Aminobisphosphonates as latency reversing agents and combination treatments for hiv cure
Lo Vasco Emerging roles of signal transduction pathways in neurodegenerative diseases. Hunting new possible therapeutic molecular targets
US11690856B2 (en) Compounds for treating CMV related diseases